CD274 and neoplasm: In the later 20th century, blockage of the interaction between PD-L1 and PD-1 was proposed as a possible therapeutic path to combat tumour growth, and studies using monoclonal antibodies targeting immune checkpoints (such as PD-L1/PD-1) started to proliferate (Figure 1D).